RNA polymerase variants

Patent metadata

Field	Value
Publication number	US-10526629-B2
Application number	US-201916432541-A
Country	US
Kind code	B2
Filing date	Jun 5, 2019
Priority date	Aug 18, 2017
Publication date	Jan 7, 2020
Grant date	Jan 7, 2020

Abstract

The present disclosure provides, in some aspects, variant RNA polymerases, the use of which increases transcription efficiency while reducing the number of double-stranded RNA contaminates and run-on transcripts produced during an in vitro transcription reaction.

First claim

What is claimed is:

1. A T7 ribonucleic acid (RNA) polymerase variant comprising an amino acid sequence having at least 90% identity to the amino acid sequence of SEQ ID NO: 1 modified to comprise an amino acid substitution at position G47, wherein the T7 RNA polymerase variant has RNA polymerase activity.

2. The T7 RNA polymerase variant of claim 1 , wherein the amino acid substitution is selected from the group consisting of alanine, isoleucine, leucine, methionine, lysine, glutamine, and glutamate.

3. The T7 RNA polymerase variant of claim 2 , wherein the amino acid substitution is alanine (G47A).

4. The T7 RNA polymerase variant of claim 1 , wherein the T7 RNA polymerase variant comprises an amino acid sequence having at least 95% identity to SEQ ID NO:1.

5. The T7 RNA polymerase variant of claim 1 comprising an additional C-terminal amino acid.

6. The T7 RNA polymerase variant of claim 5 , wherein the additional C-terminal amino acid comprises glycine (G).

7. The T7 RNA polymerase variant of claim 1 , wherein the RNA polymerase variant comprises the amino acid sequence of SEQ ID NO:3.

8. The T7 RNA polymerase variant of claim 5 comprising two additional C-terminal amino acids.

9. The T7 RNA polymerase variant of claim 8 , wherein the two additional C-terminal amino acids comprise the same type of amino acid or two different types of amino acids.

10. A T7 ribonucleic acid (RNA) polymerase variant comprising an amino acid sequence having at least 95% identity to the amino acid sequence of SEQ ID NO: 1 modified to comprise an alanine at position 47, wherein the T7 RNA polymerase variant has RNA polymerase activity.

11. The T7 RNA polymerase variant of claim 10 comprising the amino acid sequence of SEQ ID NO: 3.

12. The T7 RNA polymerase variant of claim 10 further comprising a C-terminal glycine.

13. The T7 RNA polymerase variant of claim 12 comprising the amino acid sequence of SEQ ID NO: 110.

14. A T7 RNA polymerase variant comprising the amino acid sequence of SEQ ID NO: 110.

Assignees

• Modernatx Inc

Inventors

• Rabideau Amy E
• Dousis Athanasios
• Ravichandran Kanchana
• Hobert Elissa

Classifications

• C12Y207/07006

  DNA-directed RNA polymerase (2.7.7.6) · CPC title

• C12N2320/53

  reducing unwanted side-effects · CPC title

• C12N2310/3521

  Methyl · CPC title

• C12N2310/317

  with an inverted bond, e.g. a cap structure · CPC title

• C12N15/87

  Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation · CPC title